Metabolomics in Drug Discovery & Development
Boston, MA, USA, 18/Sep/2012 to 20/Sep/2012 The world's first and only pharmaceutical-focused metabolomics meeting.
Not only will you uncover and learn how to adopt best practice from drug developers using metabolomics for commercial use. You’ll also find out how to fully integrate metabolomics with other ‘omic data generated in drug discovery and development.
The last decade of exciting academic research in metabolomics is now being applied by drug developers to determine and validate tox and safety biomarkers. Investment from drug developers is huge as the pharmaceutical industry is now using metabolomics to find novel targets, enhance experimental design and ensure clinical success. However, statistical challenges and inherent variability in data sets must be overcome to realize the full potential of this exciting technology.
Metabolomics in Drug Discovery and Development is the only meeting where you can hear cutting edge case studies from drug developers who are already reaping the benefits of metabolomics. Attend this meeting to understand how metabolomics can be used to reduce both costs and time in clinical development. You will also be brought up to speed by the FDA with the latest regulatory perspective on how to qualify biomarkers.
Join us to hear the most innovative methods and organ specific case studies fromthe likes of Pfizer, AstraZeneca and Merck. This meeting will without question help you and your organization improve your statistical design to validate biomarkers in the data.
Attend Metabolomics in Drug Discovery and Development to:
Listen to groundbreaking case studies on how metabolomics is being applied right now in drug discovery by Eli Lilly, Bayer Healthcare and Biogen Idec
Overcome challenges in statistical analysis by listening to experts from the European Bioinformatics Institute and the Netherlands Metabolomic Centre
Understand how Bayer apply metabolite profiling technology to clinical studies Hear how Merck combine metabolomic data with their existing ‘omic’ data sets
Identify the current FDA biomarker qualification process to reduce lengthy approval processes
Learn from the academic leaders as they give their perspective on how the most cutting edge research can be applied to drug discovery and development
Who Should Attend?
This meeting should be attended by industry leaders from pharma, as well as leading biotechs and academia who wish to further their knowledge of metabolomic applications in drug development. Specifically those involved in:
Biomarkers
Molecular/Companion Diagnostics
Metabolite Profiling
Clinical Development
Regulatory Affairs
R&D Strategy
Commercial/Business Development
Analytical chemistry
Event website
sbv IMPROVER Species Translation Challenge
Athens, Greece, 29/Oct/2013 to 31/Oct/2013
You are invited to participate in the sbv IMPROVER “Species Translation Challenge” that aims to:
- Identify rules that map measurements derived from systematic perturbations in one species to another
- Understand the limitation of species translatability
- Quantify the translatability between species
Why you should be part of sbv IMPROVER:
- Research grant funding for the best performing teams
- Receive an independent assessment of your methods
- Gain access to previously unpublished high quality phosphoproteomics and gene expression data
- Enhance your visibility and gain recognition in the scientific community
- Be invited as a best performer to present your approach at a Symposium in Athens, Greece, 29 – 31 October 2013
- Have your methodology be published in a peer-reviewed scientific journal if you win the challenge
The sbv IMPROVER project and
www.sbvimprover.com are part of a collaboration designed to enable scientists to learn about and contribute to the development of a new crowd sourcing method for verification of scientific data and results. The project team includes scientists from Philip Morris International’s (PMI) Research and Development department and IBM's Thomas J. Watson Research Center. The project is funded by PMI.
This is a crowdsourcing based approach (virtual event), followed by a Symposium in Athens, Greece, 29 – 31 October 2013.
Enhance the visibility of your published article
Facebook Google+ Twitter
Pinterest Tumblr YouTube